Vivos Inc (RDGL)

[SC8]

And note there isn't any evidence this "improved" process has any performance advantages over version tested and sold years prior to those "improvements".

That weak process patent can't stop generics from entering market should Radiogel ever be approved. And no worries about generics entering animal market; MK has demonstrated it's hopelessly unprofitable.